MedTrace Logo

Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma

NCT02965703 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2026-04-13

Study results available
· View outcomes & findings →

Summary

This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Colorectal Adenoma
  • Colorectal Carcinoma

Interventions

DRUG

Aspirin

Given PO

PROCEDURE

Biospecimen Collection

Undergo collection of blood, urine, stool, and rectal swab samples

OTHER

Placebo Administration

Given PO

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Rectal Biopsy

Undergo rectal biopsy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Qi Dai · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-16
Primary Completion
2023-01-31
Completion
2026-12-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02965703 on ClinicalTrials.gov